iShares MSCI India ETF vs 10X Genomics Inc — how do they compare? iShares MSCI India ETF trades at $48.84, while 10X Genomics Inc trades at $45.16 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | TXG | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $45.80 |
52-Week Low | $45.42 | $11.34 |
Market Cap | — | $5.48B |
Enterprise Value | — | $5.02B |
Signals from Pluang's Aura AI — not financial advice
INDA trades at $48.56, down 0.72% on the day, with neutral technical signals overall. The ETF shows bullish moving averages but neutral oscillators, with key support and resistance clustered around $49. Recent news highlights India's strong 7.8% GDP growth (CNBC, 2026-06-05) and ongoing comparisons with other India-focused ETFs amid foreign investor outflows.
The outlook remains mixed: India's robust economic expansion and strategic sector composition offer growth potential, but risks include geopolitical tensions, AI investment underperformance, and regulatory changes in clean energy. Analyst sentiment is cautiously optimistic, with some seeing value in INDA's discount to S&P 500 valuations.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Trailing returns across standard periods
Latest headlines on both assets
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →